Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

17.79 +0.98 (+5.83%)

Streaming Delayed Price Updated: 3:23 PM EDT, Jun 9, 2026 Add to My Watchlist

Price and Volume

Volume	741,033
Open	17.16
Bid (Size)	17.77 (300)
Ask (Size)	17.81 (300)
Prev. Close	16.81
Today's Range	16.89 - 18.00
52wk Range	8.060 - 25.00
Shares Outstanding	58,310,703
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

June 03, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Via The Motley Fool

Performance

YTD	-3.8%	-3.8%
1 Month	-3.6%	-3.6%
3 Month	+0.6%	+0.6%
6 Month	-19.9%	-19.9%
1 Year	+23.5%	+23.5%

More News

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Via The Motley Fool

Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗

March 02, 2026

Via Chartmill

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

May 26, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

May 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

Dyne Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 11, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

April 27, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

April 01, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

Via The Motley Fool

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

March 08, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

March 08, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 02, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Participate in Upcoming Investor Conferences

February 25, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

February 22, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

January 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

December 23, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 11, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗

December 10, 2025

Via The Motley Fool

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?

Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?

The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market

What is the current price of Dyne Therapeutics, Inc. - Common Stock?

The current price of Dyne Therapeutics, Inc. - Common Stock is 17.79

When was Dyne Therapeutics, Inc. - Common Stock last traded?

The last trade of Dyne Therapeutics, Inc. - Common Stock was at 06/09/26 03:23 PM ET

What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?

The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.04B

How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?

Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.